<DOC>
	<DOCNO>NCT02716805</DOCNO>
	<brief_summary>This open-label , multicenter , Phase 1 study checkpoint therapy , tremelimumab durvalumab , administer subject multiple myeloma high risk relapse . Checkpoint therapy administer prior 2 cycle post autologous stem cell transplant ( ASCT ) . This follow 6 additional monthly cycle durvalumab alone .</brief_summary>
	<brief_title>Phase 1 Study Assess Safety &amp; Tolerability Tremelimumab &amp; Durvalumab , Administered With High Dose Chemotherapy Autologous Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Histologically confirm multiple myeloma 2 . Measurable disease 3 . Available CD34+ stem cell 4 . Eligible autologous stem cell transplantation 5 . Four less prior line systemic therapy multiple myeloma 6 . Able willing provide consent require bone marrow biopsy . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 8 . Anticipated lifespan great 3 month 9 . Adequate organ function 10 . Have inform treatment option 11 . Age ≥ 18 year 12 . Able willing give valid write informed consent 1 . Prior exposure tremelimumab durvalumab antiCTLA4 , antiPD1 , antiPDL1 antibody 2 . History severe allergic reaction unknown allergen component study drug 3 . Active prior autoimmune disease except autoimmune thyroiditis , vitiligo , psoriasis require systemic therapy 4 . Prior allogeneic transplantation 5 . Any prior Grade ≥ 3 immunerelated adverse event ( irAE ) prior corticosteroidrefractory irAE 6 . Known active chronic viral hepatitis history type hepatitis within last 6 month 7 . History sarcoidosis syndrome 8 . Active history inflammatory bowel disease ( colitis , Crohn 's ) , celiac disease , serious , chronic , gastrointestinal condition associate diarrhea . Active history systemic lupus erythematosus Wegener 's granulomatosis . 9 . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available 10 . Known immunodeficiency active HIV 11 . Other active serious illness 12 . Prior treatment clinical trial involve another investigational agent within 4 week prior Day 31 study ; resolution respective adverse event Grade 1 low occur 13 . Major surgical procedure within 30 day prior Day 31 still recover prior surgery 14 . Mental impairment may compromise ability give informed consent comply requirement study 15 . Lack availability immunological clinical followup assessment . 16 . Women breastfeed pregnant evidence positive serum pregnancy test 17 . Subjects unwilling use acceptable method contraception . Female subject refrain breastfeed throughout period . 18 . Any condition , clinical judgment treat physician , likely prevent subject comply aspect protocol may put subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>autologous stem cell transplant</keyword>
	<keyword>HDT/ASCT</keyword>
	<keyword>CTLA-4</keyword>
	<keyword>PD-L1</keyword>
	<keyword>peripheral blood mononuclear cell</keyword>
	<keyword>PBMC</keyword>
	<keyword>ASCT</keyword>
</DOC>